MAP3K5 and metabolic dysfunction-associated steatohepatitis: Recent studies reported that TNFAIP3 could block the onset and progression of nonalcoholic steatohepatitis (NASH) by suppressing ASK1 hyperactivation (28) or inhibiting TAK1 activation and was also regarded as the promising therapeutic target of NASH (29).